Selective serotonine reuptake inhibitors for depression in Alzheimer-type and other dementias;Inhibiteurs de la recapture de la sérotonine dans la dépression de la maladie d'Alzheimer et autres démences

Presse Medicale

Volumn 32, Issue 25, 2003, Pages 1181-1186

  Lebert, Florence ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; PAROXETINE; PERPHENAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; ALZHEIMER DISEASE; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NAUSEA; REVIEW; TREATMENT OUTCOME; VOMITING;

AGED; ALZHEIMER DISEASE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; DEMENTIA; DEPRESSION; FLUOXETINE; HUMANS; NEUROPSYCHOLOGICAL TESTS; PAROXETINE; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TRAZODONE;

EID: 0042161639     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lebert F, Pasquier F, Petit H. Behavioral effects of fluoxetine in dementia of Alzheimer type. Int J Geriatric Psychiatry 1994; 9: 590-1.
2. Volicer L, Rheaume Y, Cyr D. Treatment of depression in advanced Alzheimer's disease using sertraline. J Geriatr Psychiatry Neurol 1994; 7: 227-9.
3. Stewart JT, Shin KJ. Paroxetine treatment of second disinhibition in dementia. Am J Psychiatry 1997; 154: S1474.
4. Burke WJ, Dewan W, Wengel SP, Roccaforte WH, Nadolny GC, Folks DG. Use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatry Psychiatry 1997; 12: 519-25.
5. Pollock BG, Mulsant BH, Sweet R et al. An open pilot study of citalopram for behavorial disturbancy of dementia. Plasma levels and real-time observations. Am J Geriatry Psychiatry 1997; 5: 70-8.
6. Nyth AL, Gottfries CG, Lyby K et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992; 86: 138-45.
7. Olafsson K, Jorgensen S, Jensen HV, Bille A, Arup P, Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992; 85: 453-6.
8. Lyketsos CG, Sheppard JM, Steele CD et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000; 157: 1686-9.
9. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001; 13: 223-40.
10. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38: 246-52.
11. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998; 13: 100-8.
12. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157: 894-901.
13. Auchus AP, Bissey-Black C, Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591-3.
14. Lanctot KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17: 531-41.
15. Pollock BG, Mulsant BH, Rosen J et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159: 460-5.
16. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303-7.
17. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001; 18: 355-68.
18. Mc Rae 2001 (résultats non publiés).
19. Simpson DM, Foster D. Improvement inorganically disturbed behavior with trazodone treatment. J Clin Psychiatry 1986; 47: 191-3.
20. Greenwald BS, Marin DB, Silvernai SM. Serotonergic treatment of screaming and banging in dementia. Lancet 1986; 2: 1464-5.
21. Lebert F, Pasquier F, Petit H. Behavorial effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994; 55: 536-8.
22. Lawlor BA, Radcliffe J, Molchan SE et al. A pilot study placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994; 9: 55-9.
23. Teri L, Logsdon RG, Peskind E et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271-8.
24. Suitzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc 2001; 49: 1294-300.
25. Tingle D. Trazodone in dementia. J Clin Psychiatry 1986; 47: 482.
26. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212-16.
27. Lebert F, Pasquier F. Tradozone in the treatment of behaviour in frontotemporal dementia. Hum Psychopharmacol Clin Exp 1999; 14: 279-81.
28. Lebert F, Delacourte F, Pasquier F. Treatment of fronto-temporal dementia. In Alzheimer's disease and related disorders annual 2002, S Gauthier & J Cummings, Dunitz eds, London: 171-182.
29. Pasquier F, Fukui I, Sarazin M et al. Laboratory investigations and treatment. Ann Neurol 2003; 53.
30. Rojas-Fernandez CH, McKnight C. Dementia with Lewy bodies: review and pharmacotherapeutic implications. Pharmacotherapy 1999; 19: 795-803.